mRNA-1083 Shows Durable Immune Response and Safety in Adults ≥50 Years
mRNA-1083 demonstrated durable antibody responses against influenza and SARS-CoV-2 for 6 months with a favorable safety profile.
Therapeutic Area
Therapeutic area intelligence for Vaccine with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.